stage heart failure is cardiac transplantation. A number of strategies to regenerate heart tissue have been devised to resolve the shortage of available transplantation organs, including transplantation of cardiomyocytes or cardiomyogenic stem cells. Stem cell research is actively pursuing strategies to yield new cell sources for use in regenerative medicine. Stem cells are classified into 2 types of cells, somatic stem cells and pluripotent stem cells.
Somatic stem cells reside in various organs such as bone marrow, brain, liver, skeletal muscle, and dermal tissue. Somatic stem cells show multipotency and a capacity for self-renewal that enable these cells to regenerate damaged tissues. However, the in vitro proliferative ability of somatic stem cells is limited. The stem cells that exhibit pluripotency are embryonic stem (ES) cells, embryonic germ cells, embryonic carcinoma cells, and induced pluripotent stem (iPS) cells. Among these pluripotent stem cells, ES cells and iPS cells are expected to be a new potential source of cells for the treatment of many different degenerative diseases, including cardiovascular diseases, as a result of their capacity for selfrenewal. The therapeutic effects of human ES cell-derived progeny have been reported in animal models for several diseases. [1] [2] [3] [4] [5] iPS cells are derived from somatic cells by introducing defined reprogramming factors, and they have the ability to differentiate into various types of somatic cells (Figure 1 ).
Discovery of iPS Cells
ES cells, which are derived from the inner cell mass of mammalian blastocysts, have the ability to proliferate robustly while maintaining both their pluripotency and the ability to differentiate into cells of all 3 germ layers. 6 Human ES cells were first derived from human blastocysts by Thomson et al 7 in 1998. iPS cells were first established in 2006 by Takahashi and Yamanaka 8 using the retrovirus-mediated transduction of 4 transcription factors (c-Myc, Oct3/4, SOX2, and Klf4) into mouse fibroblasts. These reprogrammed cells were selected by the expression of a ␤geo cassette (a fusion of the ␤galactosidase and neomycin resistance genes) driven by the mouse Fbx15 promoter. These Fbx15 iPS cells, when subcu-taneously injected into nude mice, gave rise to teratomas with histological evidence of cells differentiating into all 3 germ layers. However, Fbx15 iPS cells showed different gene expression and DNA methylation patterns compared with ES cells and failed to contribute to adult chimeras. Nanog and Oct3/4, which are closely involved in pluripotency, are used as a selection marker for iPS cells to obtain high-quality iPS cells. Those iPS cells selected by either Nanog or Oct3/4 expression successfully contribute to adult chimeras while also showing germline transmission. 9 -11 Human iPS cells were established in 2007, 12,13 9 years after the establishment of human ES cells, by the transduction of either the same set of transcriptional factors (c-Myc, Oct3/4, SOX2, Klf4) or another set of transcriptional factors (Oct3/4, SOX2, Nanog, Lin28) into human fibroblasts. These human iPS cells are similar to human ES cells in their morphology, their gene expression, and the epigenetic status of pluripotent cellspecific genes. Furthermore, these cells can differentiate into the cell types of the 3 germ layers in vitro and form teratomas in vivo.
iPS cells were initially derived from somatic cells by the retroviral or lentiviral transduction of transcriptional factors, and transgenes were randomly inserted into the genome of the hosts. However, such transgene insertions may disrupt native genes. Although the expression of the transgenes is silenced after the induction of a pluripotent stem cell state, a low level of expression may remain after successful reprogramming. This persistence of transgenic expression may render the iPS cells refractory to differentiation both in vitro and in vivo. Furthermore, the aberrant expression of oncogenic transgenes such as c-Myc may cause the development of tumors after the transplantation of iPS-derived cells. Okita et al 10 reported that the chimeras and progeny derived from iPS cells frequently showed tumor formation, and in these tumors, the retroviral expression of c-Myc was found to have been reactivated. In addition, the reprogramming efficiency of somatic cells to iPS cells was extremely low. These problems (ie, high tumorigenicity and a low reprogramming efficiency) would hinder the use of iPS technology in clinical applications.
Strenuous efforts have been made to improve the reprogramming efficiency and to establish iPS cells with either substan-tially fewer or no genetic alterations. Various growth factors and chemical compounds such as histone deacetylase inhibitor (valproic acid), Wnt3A, and ALK5 inhibitor have recently been found to improve the induction efficiency of iPS cells. 14 -17 These data suggest that chromatin modification is an important step in the reprogramming process and that some pathways such as Wnt and transforming growth factor-␤ signaling are associated with the efficiency of the reprogramming of somatic cells to iPS cells. The tumor suppressor protein p53 pathway has been reported to act as a barrier to the reprogramming of somatic cells to iPS cells; blockade of p53 also increases reprogramming efficiency. 18 -22 We have also recently reported that hypoxic cultivation enhances the efficiency of iPS cell generation from somatic cells. 23 A significant effort has been made to establish iPS cells with the transduction of a smaller number of reprogramming factors, and iPS cells can be established by 3 transcriptional factors without c-Myc (Oct3/4, Klf4, SOX2). 24, 25 Furthermore, mouse neural stem cells, with high levels of endogenous expression of c-Myc and SOX2, can be reprogrammed by 2 transcriptional factors (Oct3/4 and Klf4) or even just Oct3/4. 26, 27 The iPS cells established by either the retroviral or lentiviral transduction of the reprogramming factors have genetic modifications that occur as a result of the exogenous sequences. Several methods to deliver the transcriptional factors through means other than retroviral or lentiviral transduction have been devised to avoid such genetic modifications. The transduction of the reprogramming factors with adenoviruses, plasmid vectors, and removable transposon systems successfully reprograms the somatic cells to iPS cells. 28 -32 Moreover, it has been reported that mouse and human iPS cells can be established by the direct delivery of recombinant proteins of reprogramming factors. 33, 34 iPS cells may be established by chemical manipulation alone in the near future because some chemical compounds can improve the reprogramming efficiency.
Characterization of Pluripotent Stem Cell Clones
The characteristics of each established iPS cell line can be evaluated by several methods. 35 Reverse-transcription polymerase chain reaction and immunocytochemistry can be used to evaluate specific genes or proteins, whereas further examination of the global expression with a microarray gene expression analysis is useful. Both in vivo and in vitro differentiation should be assessed to evaluate the pluripotency of each iPS cell line. Teratoma formation is an established assay that can determine the capacity of differentiation in vivo. Embryoid body formation can be used to assess the in vitro differentiation of iPS cells.
Directed differentiation into specific cell types such as neurons can be performed to assess the differentiation capacity of iPS cell lines into particular lineages. The most stringent criterion for mouse ES/iPS cells is their ability to generate germlinecompetent adult mouse chimeras and thus germline transmission. However, germline transmission cannot be assessed with human ES/iPS cells. Teratoma formation is considered to be the essential requirement for evaluating human ES/iPS cell lines. However, whether the same criteria should be applied in the evaluation of all iPS cells remains controversial. 36, 37 To date, iPS cells have been derived from various tissues, including embryonic fibroblasts, 10 adult tail-tip fibroblasts, 24 hepatocytes, 38 gastric epithelial cells, 38 pancreatic cells, 39 neural stem cells, 26, 40, 41 and B lymphocytes 42 in the mouse, as well as skin fibroblasts, 12, 13, 43 keratinocytes, 44 and peripheral blood cells 45 in humans. It is unclear whether iPS cells derived from various tissues have the same characteristics as pluripotent stem cells.
Miura et al 46 generated neurospheres containing neural stem and progenitor cells from mouse iPS cell lines derived from embryonic fibroblasts, adult tail-tip fibroblasts, hepatocytes, and stomach epithelial cells and evaluated the teratoma-forming propensity of the secondary neurospheres. They demonstrated that the secondary neurospheres derived from tail-tip fibroblast iPS cells contained significantly higher amounts of undifferentiated cells than those from mouse embryonic fibroblast iPS cells. The neurospheres from the iPS cells derived from different tissues varied substantially with regard to their teratoma-forming propensity, which correlated with the persistence of undifferentiated cells. These data suggest that iPS cells from different origins may have a different potential for differentiation; thus, certain cell types may be better for achieving complete reprogramming with a reduced risk of teratoma formation. If some cells in the iPS clones are refractory to differentiation, then those cells could result in immature teratoma formation after transplantation to patients. Whether this propensity exists in targeted differentiation to other cell types such as cardiomyocytes remains to be elucidated.
Marked differences have been reported in the differentiation propensity between various human ES cell lines. 47 In the differentiation induction of human iPS cells, there may also be such differences in the propensity of differentiation and the persistence of cells refractory to differentiation among the clones derived from different tissues.
Generation of Cardiomyocytes From Pluripotent Stem Cells
Mouse ES cells can differentiate into various cell types, including cardiomyocytes, neuronal cells, and embryonic erythrocytes. 48 ES cell differentiation is often performed through embryoid bodies, which are aggregates of ES cells. Reproducible cardiomyocyte differentiation systems with mouse and human ES cells have also been reported using either embryoid body formation or coculture systems with other cells. 49 -53 In addition, mouse and human iPS cells can differentiate into cardiomyocytes as well as ES cells. 54 -56 However, the low efficiency of cardiomyocyte differentiation remains an important issue. Several methods of targeted differentiation from ES cells to cardiomyocytes have been devised. Yamashita et al 57 reported that the flk-1-positive cardiomyocyte progenitor cells can be induced in a 2-dimensional culture of mouse ES cells and that the coculture of the flk-1-positive progenitor cells on OP9 stroma cells yields efficient differentiation to cardiomyocytes. Recently, the authors further reported a substantial enhancement of cardiac progenitor and cardiomyocyte differentiation in their differentiation system using an immunosuppressant, cyclo-sporine-A. 58 The targeted differentiation toward cardiomyocytes from human ES cells can be successfully achieved by supplementation of signaling molecules such as activin A and bone morphogenetic protein-4. 2, 4 Some small molecules have the potential to enhance the differentiation from ES cells to specific tissue cells, and a high-throughput screening system has been used to identify such small molecules. 59, 60 The highthroughput screening system revealed that ascorbic acid enhances the differentiation of ES cells into cardiomyocytes. 61 The cardiomyocytes derived from ES/iPS cells consist of several subtypes of cardiomyocytes, including atrial, sinus nodal, and ventricular cardiomyocytes. These subtypes show different forms of action potential and can be isolated by electrophysiological analysis. Some cardiac subpopulationspecific reporters have also been reported to be useful to discriminate subtypes of cardiomyocytes [62] [63] [64] (see Table) .
The differentiation of ES cells to cardiomyocytes mimics the developmental process in embryos ( Figure 2) . Therefore, several studies have focused on the development of cardiac tissue during ES cell differentiation in vitro. 48, [65] [66] [67] [68] [69] [70] Moreover, the recent availability of human ES/iPS cells and the capacity of human ES/iPS cells to differentiate into cardiac myocytes make the study of the development of human cardiac myocytes possible and suggest the potential use of ES/iPS-derived cardiomyocytes for the pathogenetic study of disease-specific cells, screening for new drugs, and clinical application of cell therapy.
Stem Cell-Based Cardiac Regeneration
The transplantation of either cardiomyocytes or cardiac progenitor cells derived from human ES cells into the infarcted hearts of rodents has been reported to improve cardiac function 2,4,71-73 (Figure 3 ). Transplanted ES/iPS cell-derived cardiac cells have been shown to integrate into treated hearts and to improve cardiac function. However, the precise mechanisms mediating this effect are currently unknown. 74 The majority of the grafted rat primary cardiomyocytes and ES-derived cardiomyocytes disappear within several days after transplantation by direct injection into hearts. 2, 75 To enhance the effect of stem cell-based cardiac regeneration, it is important to improve the survival of grafted cells. The administration of prosurvival factors with the grafted cells improves the survival of transplanted ES cell-derived cardiomyocytes. 2 In addition, the formation of aggregates of ES/iPS cell-derived cardiomyocytes through homophilic cell-cell adhesion improves their survival in the immunodeficient mouse heart. 76 Shimizu et al 77 reported that the repeated transplantation of layered cell sheets of cultured rat neonatal cardiomyocytes yields an Ϸ1-mm-thick myocardium with a well-organized microvascular network. These new successfully treated with iPS cells. 78 -80 Nelson et al 81 reported the intramyocardial delivery of iPS cells derived from mouse embryonic fibroblasts to successfully restore postischemic cardiac function while achieving the in situ regeneration of cardiac, smooth muscle, and endothelial tissue. The transplantation of undifferentiated ES/ iPS cells results in the formation of teratomas. Teratoma formation in treated hearts may cause life-threatening events such as fatal arrhythmias, cardiac tamponade, and heart failure. Therefore, it is necessary to remove undifferentiated cells from the grafts and to eliminate the risk of teratoma formation. Purification of cardiac cells is crucial to eliminate the remaining undifferentiated cells. Manual dissection of beating areas or discontinuous Percoll density gradient centrifugation can be used to purify cardiomyocytes, but the efficiency of purification with these methods is relatively low. ES/iPS cell lines with cardiomyocyte-specific reporters can also be used for the high-grade purification of cardiomyocytes. 82, 83 However, this method requires genetic modification. Hattori et al 76 reported that a fluorescent dye that labels mitochondria could be used to selectively mark ES/iPS cell-derived cardiomyocytes. They demonstrated that highly pure cardiomyocytes (Ͼ99% purity) could be obtained by fluorescence-activated cell sorting with this dye. Such nongenetic methods can be powerful tools in clinical settings. Some iPS cell lines may contain cells that are refractory to differentiation. Therefore, it is also important to choose the iPS cell lines that do not contain refractory undifferentiated cells after undergoing differentiation induction procedures.
Several studies found no teratomas in the heart after transplantation of cardiomyocytes or cardiac progenitors derived from ES cells. 2, 4 These data suggest that the risk of teratoma formation might be quite low after the transplantation of cardiomyocytes that have been appropriately purified. However, further investigation is required to eliminate the potential risk of teratoma formation.
Nelson et al 81 reported that although the intramyocardial delivery of undifferentiated iPS cells within infarcted hearts of immunodeficient mice produced gradual outgrowth of teratomas, the transplantation of undifferentiated iPS cells produced stable engraftment without any detectable tumor formation in the infarcted hearts of immunocompetent recipients. These results showed that infarcted hearts in an immunocompetent host provided a permissive environment for differentiation and demonstrated the therapeutic potential of iPS cells for myocardial infarction. However, the possibility of a teratoma forming from the remaining undifferentiated cells is one of the most important issues in cell therapy with ES/iPS cells. The transplantation of undifferentiated pluripotent stem cells may therefore have the potential to induce both cardiac regeneration and teratoma formation simultaneously. Further analysis of the therapeutic potential of ES/iPS cells and their progeny and of teratoma-or tumor-forming propensity in animal models with long-term follow-up is therefore required before cell therapy with human iPS cells can advance to clinical trials.
Investigation of Disease-and Patient-Specific iPS Cells
Disease-specific pluripotent stem cells capable of differentiation into various tissues could provide new insights into the patho-physiology of various diseases by permitting the analysis of a system that is close to that of humans. iPS cells have been established from patients with adenosine deaminase deficiency, Schwachman-Bodian-Diamond syndrome, Gaucher disease, Duchenne and Becker muscular dystrophy, Parkinson disease, Huntington disease, type 1 diabetes mellitus, Down syndrome, Lesch-Nyhan syndrome, amyotrophic lateral sclerosis, spinal muscular atrophy, and Fanconi anemia. 84 -88 Disease-specific iPS cells from patients with such heart diseases as congenital long-QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular cardiomyopathy, and other genetic arrhythmias may shed some light on these disease mechanisms, thereby resulting in the discovery of new therapies. Experimental mouse model systems have been used to understand the functional changes of genetic mutations identified in patients with inherited arrhythmias because of the ease with which molecular genetic strategies can be applied. However, the mouse models do not always demonstrate the same phenotypes as those seen in humans because the type and/or distribution of cardiac ion channels are different from those of humans and demonstrate shorter action potential duration and higher heart rate (Ϸ600 bpm) in mice. 89 -91 An in vitro analysis of human cardiomyocytes is therefore important to understand the mechanism of human genetic arrhythmias. Mutations of genes encoding potassium, sodium and calcium channels, or membrane adaptors have been reported to be responsible for congenital long-QT syndrome. [92] [93] [94] [95] However, only 50% to 75% of the probands can be diagnosed through genetic testing. 96 The reduction of outward potassium current (I Ks , I Kr , or I K1 ) or increase of inward current (I Na or I Ca ) (Figure 4 ) leads to prolongation of the cardiac action potential duration, resulting in a prolonged QT interval and torsade de pointes. Recording each ion channel current of the ventricular cardiomyocytes derived from patient-specific iPS cells with the whole-cell patch-clamp method is expected to reveal diagnostic abnormalities of these currents. The detection of abnormal currents in the patients whose genetic mutation is unknown will be helpful not only for understanding of their pathological mechanisms but also for managing the patients. Screening of the drugs that can correct the abnormalities of such currents might also help to develop appropriately personalized therapy for each patient.
Congenital heart defects are among the most common birth defects. Some congenital heart defects are thought to be caused by a genetic predisposition. Gain-of-function and loss-of-function mutations of specific genes have been shown to be related to the development of congenital heart defects in an experimental mouse model. 97 However, the mechanisms of the development of human congenital heart defects are still poorly understood. The study of cardiomyocytes derived from iPS cells from the patients with congenital heart defects may provide a new and better understanding of the development of congenital heart defects.
The selection of normal control subjects is one of the important issues in patient-specific iPS cell research. In monogenic disorders, iPS cell lines derived from healthy family members may be optimal because of the close genetic background. However, iPS cells are not always available from family members. In addition, there may be variations in the characteristics of iPS cell-derived cardiomyocytes between iPS cell lines; thus, an analysis of differentiated cells from several iPS cell lines is necessary to confirm the reproducibility of the results.
Conclusions
This discovery of iPS cells has opened up new avenues to generate patient-and disease-specific pluripotent stem cells. Human iPS cells may be useful for understanding the mechanisms of diseases and for drug screening. Moreover, the iPS cell technology may play a major role in regenerative therapy in the future. However, iPS cell technology has several issues that remain to be overcome, including the present low efficiency of iPS cell generation without genetic alterations, the possibility of tumor formation in vivo, and unregulated growth of the remaining cells that are partially reprogrammed and refractory to differentiation. These issues must be solved before iPS technology can be successfully used in clinical applications. 
